the moderna covid19 vaccine is prepared for administration ahead of a free distribution of over the counter rapid covid19 test kits to people receiving their vaccines or boosters at union station in los angeles california on january 7 2022 moderna on thursday said it expects to sell at least 19 billion of its covid19 vaccine this year after reporting fourthquarter earnings that blew out analysts earnings and revenue estimates heres how the company performed compared to what wall street expected based on analysts average estimates compiled by refinitiv modernas covid vaccine is the companys only commercially available treatment the twodose vaccine spikevax was fully approved for adults ages 18 and older in the last month by the food and drug administration and the centers for disease control and prevention moderna is conducting a clinical trial for a booster shot that specifically targets the omicron covid variant however its unclear whether there will be strong demand for an omicron booster as new infections from the variant drop sharply in the us and other parts of the world ceo stephane bancel told cnbc last week the pandemic may be in its final stage though he said people older than 50 and those with underlying conditions will need a booster once a year theres an 80 chance that as omicron evolves or sarscov2 virus evolves we are going to see less and less virulent viruses bancel told squawk box asia however he said theres a 20 scenario where we see a next mutation which is more virulent than omicron